Baroreflex Device Eases HF Symptoms
A novel implanted neuromodulation device substantially improved quality of life and functional capacity in heart failure with reduced ejection fraction (HFrEF) in the BeAT-AF study. Baroreflex stimulation with the Barostim Neo device also improved the key prognostic biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP) in the subset of patients with a baseline level of 1,600 pg/mL or less, reflecting less advanced heart failure.
To continue reading this article
Continue reading your article with a eMediNexus account.